蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1704|回复: 1
收起左侧

【外媒】Baxter将在新加坡投资重组蛋白基地

[复制链接]
药生
发表于 2014-8-12 09:24:58 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
小编:Baxter也开始了中南亚的投资和市场扩张?也许吧……新加坡是个好地方,但真心不觉得把重组蛋白的基地投资在新加坡是一件好事。毕竟在亚太地区,新加坡的税收政策、劳工薪资怎么算都不适合进行科技、实业的投资,毕竟人家地方小,又有钱么……但是在那里有个基地,然后把工厂搬到印度、印尼、马来西亚倒是不错的选择,还很近。

以下是外媒的新闻稿:

Baxter to add recombinant protein processing suite at Singapore plant

August 11, 2014 | By Nick Paul Taylor

In the 11 years since the Singapore government created a biologics CMO to kickstart the local sector, a who's who of biopharma manufacturers have opened plants in the country. Baxter ($BAX) is among the latest to set up shop in Singapore and is already pushing ahead with expansion plans.
The Deerfield, IL-based drugmaker officially opened the Singapore facility--which supports the processing of hemophilia A treatment Advate--this week. At the ceremony, Baxter revealed plans to add a second recombinant protein processing suite at the facility. The new capacity will initially process hemophilia B treatment Rixubis, with recombinant factor VIII treatment BAX 855 being added if it successfully completes Phase III and wins approval.
Baxter now has three facilities handling Advate processing, a network the company has built to ensure it can maintain output. The drug is an important part of Baxter's $3.4-billion-a-year hemophilia business. And the franchise will become even more significant for the company if plans to split its biopharma and med tech units go ahead. The Singapore plant and the 450 people it will employ once the expansion is completed next year will be a cornerstone of the independent biopharma company.
That Baxter chose to join the likes of AbbVie ($ABBV), Genentech and Novartis ($NVS) in opening a biologics plant in Singapore is at least partly due to the country's Economic Development Board, a group that has worked for years to develop the nation's workforce and lure drugmakers. "Singapore EDB will continue to invest in talent development, supporting infrastructure and new technologies to support the biologics sector," Yeoh Keat Chuan, managing director of the EDB, said in a statement.
回复

使用道具 举报

发表于 2014-8-12 11:28:03 | 显示全部楼层
lonza也在那里,呵呵
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-3-16 03:06

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表